Microangiopathic hemolytic anemia as a complication of diabetes mellitus

American Journal of the Medical Sciences

Volumn 315, Issue 3, 1998, Pages 211-215

  James, Sam H ^a,b   Meyers, Anthony M ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b UNIVERSITY OF ARIZONA MEDICAL CENTER   (United States)

Author keywords

Antiplatelet agents; Diabetes; Diabetic microangiopathy; Microangiopathic hemolytic anemia

Indexed keywords

ANTITHROMBOCYTIC AGENT; CHOLESTEROL; CREATININE; FERROUS SULFATE; HEMOPEXIN; LACTATE DEHYDROGENASE; PENTOXIFYLLINE; PHOSPHOLIPID;

ADULT; ARTICLE; CASE REPORT; CELL MEMBRANE; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; ERYTHROCYTE MEMBRANE; HEMOLYSIS; HUMAN; KIDNEY BIOPSY; MALE; MICROANEURYSM; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; THROMBOCYTE COUNT; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 0031942758     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-199803000-00013     Document Type: Article

References (24)

1. Tooke JE. Microvascular haemodynamics in diabetes mellitus. Clin Sci. 1986;70:119-25.
2. Zatz R, Brenner BM. Pathogenesis of diabetic microangiopathy: the hemodynamic view. Am J Med. 1986;80:443-52.
3. Barnett AH. Origin of the microangiopathic changes in diabetes. Eye. 1993;7(2):218-22.
4. Przybylska M, Bryszewska M, Chapman IV. Thermal properties and fluidity of human erythrocyte membranes in diabetes mellitus. Int J Radiat Biol. 1993;63(3):419-24.
5. Labrouche S, Freyburger G, Gin H, Boisseau MR, Cassagne C. Changes in phospholipid composition of blood cell membranes (erythrocyte, platelet, and polymorphonuclear) in different types of diabetes: clinical and biological correlations. Metabolism. 1996;45(1):57-71.
6. Ruiz-Gutierrez V, Stiefel P, Villar J, Garcia-Donas MA, Acosta D, Carneado J. Cell membrane fatty acid composition in type I (insulin-dependent) diabetic patients: relationship with sodium transport abnormalities and metabolic control. Diabetalogia. 1993;36(9):850-6.
7. Brunning RD, Jacob HS, Brenckman WD, Jimenez-Pasquau F, Goetz FC. Fragmentation haemolysis in patients with severe diabetic angiopathy. Br J Haematol. 1976;34:283-9.
8. Dupont AG, Van Der Niepen P, Sennesael J, Somers G. Diabetic microangiopathic hemolytic anemia: beneficial effect of an antiplatelet agent? Diabetes Care. 1985;8(2):169-71.
9. Morita H, Suwa T, Daidah H, Takeda N, Ishizuka T, Yasuda K. Case report: diabetic microangiopathic hemolytic anemia and thrombocytopenia with antiphospholipid syndrome. Am J Med Sci. 1996;311(3):148-51.
10. Harris RC, Ismail N. Extrarenal complications of the nephrotic syndrome. Am J Kidney Dis. 1994;23(4):477-97.
11. Bryszewska M, Watala C, Torzecka W. Changes in fluidity and composition of erythrocyte membranes and in composition of plasma lipids in Type I diabetes. Br J Haematol. 1986;62:111-6.
12. Brownlee M, Vlassara H, Cerami A. Nonenzymatic glycosylation and the pathogenesis of diabetic complications. Ann Intern Med. 1984;101:527-37.
13. Panak E, Maffrand JP, Picard-Fraire C, Vallee E, Blanchard R, Roncucci R. Ticlopidine: a promise for the prevention and treatment of thrombosis and its complications. Haemostasis. 1983;13(suppl1):1-54.
14. Aviado DM, Dettelbach HR. Pharmacology of pentoxifylline: a hemorheologic agent for the treatment of intermittent claudication. J Vasc Dis. 1984;35(7):407-17.
15. Solerte SB, Ferrari E. Diabetic retinal vascular complications and erythrocyte filtrability: results of a 2-year follow-up study with pentoxifylline. Pharmatherapeutica. 1985; 4(6):341-50.
16. Abbate SL, Hoogwerf BJ. Hemolytic anemia associated with sulfonylurea use. Diabetes Care. 1990;13(8):904-5.
17. Malacarne P, Castaldi G, Bertusi M, Zavagli G. Tolbutamide-induced hemolytic anemia. Diabetes. 1977;26(2):156-8.
18. Pavlic GJ. Possible potentiation of hemolytic anemia by tolbutamide. JAMA. 1966;197(1):57-9.
19. Or R, Merin E, Stupp Y, Matzner Y. Chlorpropamide-induced hemolytic anemia. Drug Intell Clin Pharm. 1984;18:981-2.
20. Shilo S, Werner D, Hershko C. Acute hemolytic anemia caused by severe hypophosphatemia in diabetic ketoacidosis. Acta Haemat. 1985;73:55-7.
21. Manzanares JM, Conget I, Rodriguez-Villar C, Tassies D, Fernandez-Fernandez F, Cervera R, et al. Antiphospholipid syndrome in a patient with type I diabetes presenting as retinal occlusion [letter]. Diabetes Care. 1996; 10(1):92-4.
22. Henriksen R, Sogaard PE, Grennert L, Hansen BU, Manthorpe R, Nilsson IM. Autoimmune antibodies and pregnancy outcome in women with false-positive syphilis test results: a retrospective controlled investigation of women from 5170 deliveries. Acta Obstet Gynecol Scand. 1989;68:537-40.
23. Gellady AM, Greenwood RD. G-6-PD hemolytic anemia complicating diabetic ketoacidosis. J Pediatr. 1972; 80(6):1037-8.
24. Aoki Y, Yazaki K, Shirotori K, Oguchi H, Kiyosawa K, Furuta S. Insulin-dependent diabetes mellitus showing microangiopathic hemolytic anemia and chronic disseminated intravascular coagulation. Intern Med. 1992;31(11):1310-2.